Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial.
Nuplazid did not improve symptoms as an adjunctive treatment in adult patients with schizophrenia who had shown persistent inadequate response to their current antipsychotic therapy.
In a trial of 396 patients with moderate-to-severe psychotic symptoms, the drug did not show statistically significant improvements when given on top of patients existing antipsychotic treatments, compared to placebo.
![[column] Toekomst tijdschriften glanst als nooit tevoren](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/happy-couple-in-t-shirts-reading-newspaper-while-h-2024-11-10-00-13-23-utc-1-80x60.jpg)
![[column] MarketingAffairs 17: Marketing als oplossing](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/asian-seo-manager-writing-on-glass-with-illustrati-2024-11-17-23-11-51-utc-1-80x60.jpg)
